BRPI0719469C1 - vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampo - Google Patents
vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampoInfo
- Publication number
- BRPI0719469C1 BRPI0719469C1 BRPI0719469A BRPI0719469A BRPI0719469C1 BR PI0719469 C1 BRPI0719469 C1 BR PI0719469C1 BR PI0719469 A BRPI0719469 A BR PI0719469A BR PI0719469 A BRPI0719469 A BR PI0719469A BR PI0719469 C1 BRPI0719469 C1 BR PI0719469C1
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- producing
- cells
- measles
- recombinant
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 241000712079 Measles morbillivirus Species 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title abstract 3
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002458 infectious effect Effects 0.000 title abstract 2
- 241001430294 unidentified retrovirus Species 0.000 title 1
- 201000005505 Measles Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 241001493065 dsRNA viruses Species 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000711513 Mononegavirales Species 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001177 retroviral effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06292025.1A EP1939214B1 (en) | 2006-12-22 | 2006-12-22 | Cells and methodology to generate non-segmented negative-strand RNA viruses |
| EP06292025.1 | 2006-12-22 | ||
| PCT/IB2007/004444 WO2008078198A2 (en) | 2006-12-22 | 2007-12-21 | Cells and methodology to generate non-segmented negative-strand rna viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0719469A2 BRPI0719469A2 (pt) | 2014-02-11 |
| BRPI0719469B1 BRPI0719469B1 (pt) | 2019-07-02 |
| BRPI0719469C1 true BRPI0719469C1 (pt) | 2021-05-25 |
Family
ID=37831098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0719469A BRPI0719469C1 (pt) | 2006-12-22 | 2007-12-21 | vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampo |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8586364B2 (enExample) |
| EP (2) | EP1939214B1 (enExample) |
| JP (2) | JP5902371B2 (enExample) |
| KR (1) | KR101469007B1 (enExample) |
| CN (2) | CN104745533A (enExample) |
| BR (1) | BRPI0719469C1 (enExample) |
| CA (1) | CA2673262C (enExample) |
| DK (2) | DK1939214T3 (enExample) |
| ES (2) | ES2423518T3 (enExample) |
| MX (1) | MX2009006755A (enExample) |
| WO (1) | WO2008078198A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2427139T3 (es) | 2002-06-20 | 2013-10-29 | Institut Pasteur | Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna |
| EP1375512B1 (en) | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
| CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| WO2012038832A2 (en) * | 2010-09-24 | 2012-03-29 | Institut Pasteur | Generation of replicating chimeric measles virus - retrovirus particles |
| CN103906843B (zh) * | 2011-06-08 | 2016-12-07 | 维什瓦斯·乔希 | 双质粒哺乳动物表达系统 |
| FR2994697B1 (fr) * | 2012-08-24 | 2016-05-13 | Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) | Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention |
| EP2712871A1 (en) | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| EP2759301A1 (en) | 2013-01-24 | 2014-07-30 | Institut Pasteur | Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus) |
| US20140255447A1 (en) * | 2013-03-05 | 2014-09-11 | Biomune Company | Production of avian embryo cells |
| WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
| GB2583296A (en) | 2015-01-05 | 2020-10-21 | Seagull Biosolutions Pvt Ltd | Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of |
| EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| EP3255056A1 (en) * | 2016-06-06 | 2017-12-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses |
| EP3622078A1 (en) | 2017-05-09 | 2020-03-18 | Invectys | Recombinant measles vaccine expressing htert |
| EP3412307A1 (en) | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
| CN107557340A (zh) * | 2017-09-26 | 2018-01-09 | 南京普菲科医药科技有限公司 | 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用 |
| MX2020004833A (es) | 2017-11-09 | 2021-01-08 | Pasteur Institut | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. |
| US11976305B2 (en) | 2017-12-21 | 2024-05-07 | Institut Pasteur | Lassa vaccine |
| EP3820884B1 (en) * | 2018-07-13 | 2025-09-03 | Valneva SE | Method for rescuing and producing a virus in avian cells |
| CN109355301A (zh) * | 2018-08-22 | 2019-02-19 | 深圳大学 | 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身 |
| CN111218474A (zh) * | 2018-11-23 | 2020-06-02 | 成都生物制品研究所有限责任公司 | 一种副粘病毒的拯救系统和副粘病毒拯救方法 |
| EP3673917A1 (en) | 2018-12-28 | 2020-07-01 | Themis Bioscience GmbH | Norovirus vaccines |
| CN109913423A (zh) * | 2019-03-27 | 2019-06-21 | 扬州大学 | 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用 |
| EP3865180A1 (en) | 2020-02-13 | 2021-08-18 | Institut Pasteur | Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses |
| AU2021218985A1 (en) | 2020-02-13 | 2022-08-25 | Institut Pasteur | Measles-vectored COVID-19 immunogenic compositions and vaccines |
| US20230310581A1 (en) * | 2020-04-27 | 2023-10-05 | Ohio State Innovation Foundation | A live attenuated measles virus vectored vaccine for sars-cov-2 |
| EP3936517A1 (en) * | 2020-07-08 | 2022-01-12 | Institut Pasteur | An improved measles virus vaccine vector based on multiple tandem additional transcription units |
| US20240093233A1 (en) | 2021-01-13 | 2024-03-21 | Viroxis | Measles-hiv or measles-htlv vaccine |
| US20250304921A1 (en) * | 2022-05-27 | 2025-10-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Reverse genetics system for feline morbillivirus |
| EP4501946A1 (en) | 2023-07-31 | 2025-02-05 | LoopLab Bio GmbH | Self-amplifying biologics for targeted therapy |
| WO2026013289A1 (en) | 2024-07-12 | 2026-01-15 | Institut Pasteur | Measles-mumps-rubella (mmr) vaccines |
| CN120648655B (zh) * | 2025-08-21 | 2026-02-13 | 内蒙古自治区农牧业科学院 | 一株t7-293t细胞及其在牛副流感病毒3型感染性克隆拯救病毒中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0780475B2 (en) * | 1995-08-09 | 2006-07-19 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Process for the production of infectious negative-strand RNA viruses |
| HK1050210B (en) | 1999-10-12 | 2007-08-24 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| CA2412257A1 (en) | 2000-06-16 | 2001-12-20 | Institut Pasteur | Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| ES2427139T3 (es) | 2002-06-20 | 2013-10-29 | Institut Pasteur | Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna |
| DE10234579A1 (de) * | 2002-07-30 | 2004-02-12 | Zf Friedrichshafen Ag | Getriebe |
| WO2004113517A2 (en) * | 2003-06-09 | 2004-12-29 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
| EP2361974A1 (fr) | 2003-12-02 | 2011-08-31 | Institut Pasteur | Utilisation des proteines et des peptides codés par le genome d'une nouvelle souche de coronavirus associé au SRAS |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| WO2006108241A1 (en) * | 2005-04-14 | 2006-10-19 | The University Of Queensland | Immunomodulating compositions and uses therefor |
-
2006
- 2006-12-22 DK DK06292025.1T patent/DK1939214T3/da active
- 2006-12-22 ES ES06292025T patent/ES2423518T3/es active Active
- 2006-12-22 EP EP06292025.1A patent/EP1939214B1/en active Active
-
2007
- 2007-12-21 BR BRPI0719469A patent/BRPI0719469C1/pt active IP Right Grant
- 2007-12-21 DK DK07870468.1T patent/DK2091962T3/en active
- 2007-12-21 JP JP2009542273A patent/JP5902371B2/ja active Active
- 2007-12-21 CN CN201510019183.6A patent/CN104745533A/zh active Pending
- 2007-12-21 ES ES07870468.1T patent/ES2686168T3/es active Active
- 2007-12-21 MX MX2009006755A patent/MX2009006755A/es active IP Right Grant
- 2007-12-21 KR KR1020097015426A patent/KR101469007B1/ko active Active
- 2007-12-21 US US12/448,468 patent/US8586364B2/en active Active
- 2007-12-21 WO PCT/IB2007/004444 patent/WO2008078198A2/en not_active Ceased
- 2007-12-21 EP EP07870468.1A patent/EP2091962B1/en active Active
- 2007-12-21 CN CN200780047473A patent/CN101631798A/zh active Pending
- 2007-12-21 CA CA2673262A patent/CA2673262C/en active Active
-
2013
- 2013-10-15 US US14/054,748 patent/US9499799B2/en active Active
-
2014
- 2014-08-22 JP JP2014169418A patent/JP2015015955A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0719469B1 (pt) | 2019-07-02 |
| EP2091962B1 (en) | 2018-07-04 |
| EP1939214A1 (en) | 2008-07-02 |
| US8586364B2 (en) | 2013-11-19 |
| CA2673262C (en) | 2019-03-05 |
| CN104745533A (zh) | 2015-07-01 |
| JP2015015955A (ja) | 2015-01-29 |
| JP2010512779A (ja) | 2010-04-30 |
| US20100144040A1 (en) | 2010-06-10 |
| EP2091962A2 (en) | 2009-08-26 |
| KR101469007B1 (ko) | 2014-12-05 |
| US9499799B2 (en) | 2016-11-22 |
| EP1939214B1 (en) | 2013-07-10 |
| US20140051148A1 (en) | 2014-02-20 |
| BRPI0719469A2 (pt) | 2014-02-11 |
| WO2008078198A2 (en) | 2008-07-03 |
| DK1939214T3 (da) | 2013-10-14 |
| DK2091962T3 (en) | 2018-10-08 |
| ES2423518T3 (es) | 2013-09-20 |
| JP5902371B2 (ja) | 2016-04-13 |
| CN101631798A (zh) | 2010-01-20 |
| WO2008078198A3 (en) | 2008-10-30 |
| MX2009006755A (es) | 2009-07-31 |
| ES2686168T3 (es) | 2018-10-16 |
| CA2673262A1 (en) | 2008-07-03 |
| KR20090103922A (ko) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghattas et al. | Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities | |
| MX2009006755A (es) | Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. | |
| EP2010557B1 (en) | High titer recombinant influenza viruses for vaccines | |
| ES2539514T3 (es) | Métodos y composiciones para expresar ARN viral de sentido negativo en células de canino | |
| EA200801221A1 (ru) | Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк | |
| NZ596823A (en) | Swine influenza hemagglutinin variants | |
| BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
| BR112013020070A8 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
| Duan et al. | Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases | |
| BR112015002131A2 (pt) | vacina de vírus sincicial respiratório (rsv) de vírus vaccínia ancara modificado recombinante | |
| AR039465A1 (es) | Sistema multi plasmid para la produccion de virus influenza | |
| BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
| JP2012531205A5 (enExample) | ||
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| MX2018006627A (es) | Aumentar el rendimiento de particulas similares a virus en plantas. | |
| WO2016201127A1 (en) | Methods of optimizing nucleotide sequences encoding engineered influenza proteins | |
| CA3234653A1 (en) | Influenza vaccines | |
| RU2013128744A (ru) | Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками | |
| AR069885A1 (es) | Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional | |
| WO2005115448A8 (en) | Multi plasmid system for the production of influenza virus | |
| Zheng et al. | Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges | |
| Steel | New strategies for the development of H5N1 subtype influenza vaccines: progress and challenges | |
| RU2011137404A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| MX2024003420A (es) | Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente. | |
| AR110626A1 (es) | Paramixovirus y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2530 DE 02/07/2019, QUANTO AO ENDERECO DA DEPOSITANTE. |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |